Literature DB >> 28599454

Differential expression of the Notch1 receptor, and its ligands Dll1, Dll3 and Dll4 in distinct human pituitary adenoma subtypes.

Jianfu Zhang1,2, Hua Gao1, Yazhuo Zhang1.   

Abstract

Pituitary adenoma (PA) is a common type of benign tumor of the pituitary gland that is characterized by specific signs and symptoms, primarily associated with hypersecretion of pituitary glycoprotein hormones (thyroid-stimulating, growth and adrenocorticotrophic hormones, and prolactin). Surgery is the first-line treatment, although postoperative residual tissues/cells and subsequent recurrence remain notable complications. Gene therapy is an effective approach for treatment, as previous studies have demonstrated that the Notch signaling pathway participates in the pathogenesis of PA. The focus of the present study was on the associations between the expression of the Notch1 receptor and its ligands δ-like canonical Notch ligand (Dll) 1, Dll3 and Dll4 in patients with PA. Using reverse transcription-quantitative polymerase chain reaction and western blot analyses, to the best of our knowledge, this is the first study to provide a description of the differential expression of the Notch1 receptor and its ligands Dll1, Dll3, and Dll4 in various types of human PA at the mRNA and protein levels. The results of the present study demonstrated that Notch1 protein expression was positively correlated with Dll4 protein expression, but negatively correlated with Dll3 protein expression, indicating synergistic effects between the Notch1 receptor and Dll4 ligand. Furthermore, the Dll3 ligand may be an inhibitor of the Notch1 receptor, indicating an antagonistic association between Notch1 and the Dll3 ligand. These results have identified a potential target for the treatment of patients with PA.

Entities:  

Keywords:  Notch signaling pathway; notch1; pathogenesis; pituitary adenoma; δ-like canonical Notch ligand-1; δ-like canonical Notch ligand-3; δ-like canonical Notch ligand-4

Year:  2017        PMID: 28599454      PMCID: PMC5453187          DOI: 10.3892/ol.2017.5997

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  42 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Inhibition of delta-like-4-mediated signaling impairs reparative angiogenesis after ischemia.

Authors:  Ayman Al Haj Zen; Atsuhiko Oikawa; Miriam Bazan-Peregrino; Marco Meloni; Costanza Emanueli; Paolo Madeddu
Journal:  Circ Res       Date:  2010-05-27       Impact factor: 17.367

Review 3.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

4.  Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis.

Authors:  Mats Hellström; Li-Kun Phng; Jennifer J Hofmann; Elisabet Wallgard; Leigh Coultas; Per Lindblom; Jackelyn Alva; Ann-Katrin Nilsson; Linda Karlsson; Nicholas Gaiano; Keejung Yoon; Janet Rossant; M Luisa Iruela-Arispe; Mattias Kalén; Holger Gerhardt; Christer Betsholtz
Journal:  Nature       Date:  2007-01-28       Impact factor: 49.962

Review 5.  Clinically non-functioning pituitary adenoma.

Authors:  Craig A Jaffe
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

6.  Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma.

Authors:  Kumaravel Somasundaram; Sreekanth P Reddy; Katyayni Vinnakota; Ramona Britto; Madhavan Subbarayan; Sandeep Nambiar; Aparna Hebbar; Cini Samuel; Mitesh Shetty; Hari Kishore Sreepathi; Vani Santosh; Alangar Sathyaranjandas Hegde; Sridevi Hegde; Paturu Kondaiah; M R S Rao
Journal:  Oncogene       Date:  2005-10-27       Impact factor: 9.867

Review 7.  Non-functioning pituitary adenomas.

Authors:  Yona Greenman; Naftali Stern
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-10       Impact factor: 4.690

8.  Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells.

Authors:  Sanne Weijzen; Paola Rizzo; Mike Braid; Radhika Vaishnav; Suzanne M Jonkheer; Andrei Zlobin; Barbara A Osborne; Sridevi Gottipati; Jon C Aster; William C Hahn; Michael Rudolf; Kalliopi Siziopikou; W Martin Kast; Lucio Miele
Journal:  Nat Med       Date:  2002-08-19       Impact factor: 53.440

9.  Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis.

Authors:  Dusan Djokovic; Alexandre Trindade; Joana Gigante; Marina Badenes; Lilliana Silva; Ren Liu; Xiuqing Li; Ming Gong; Valery Krasnoperov; Parkash S Gill; Antonio Duarte
Journal:  BMC Cancer       Date:  2010-11-23       Impact factor: 4.430

10.  Overexpression of the Notch3 receptor and its ligand Jagged1 in human clinically non-functioning pituitary adenomas.

Authors:  Runchun Lu; Hua Gao; Hongyun Wang; Lei Cao; Jiwei Bai; Yazhuo Zhang
Journal:  Oncol Lett       Date:  2013-01-07       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.